Good morning, ladies and gentlemen, and thank you for joining Dr. Howard Berger and me today to discuss RADNET's first quarter 2026 financial results. On this call, we have also invited Case Westorp, President and CEO of Digital Health, and Shamsoka, Chief Operating and Technical Officer of Digital Health, who will share additional information about the progress of the Digital Health Operating Segment. Before we begin today, we'd like to remind everyone of the Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically statements concerning anticipated future financial and operating performance, Radnet's ability to grow the by generating patient referrals and contracts with radiology practices, recruiting and retaining technologists, receiving third-party reimbursement for diagnostic imaging services, successfully integrating acquired operations, generating revenue and adjusted EBITDA for the acquired operations as estimated, among others, are forward-looking statements within the meaning of the safe harbor. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause RADNET's actual results to differ materially from the statements contained herein. These risks and uncertainties include those risks set forth in RADNET's reports filed with the SEC from time to time, including RADNET's annual report on Form 10-K for the the year ended December 31st, 2025. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date it is made. Radnet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. And with that, I'd like to turn the call over to Dr. Berger.

Thank you, Mark. Good morning, everyone, and thank you for joining us today. On today's call, Mark, Case, Shum, and I are trying to provide you with highlights from our first quarter 2026 results, give you more insight into the factors which affected this performance, and discuss our future strategy. After all, for a fair amount, we will open the call to your questions. I'd like to thank all of you for your interest in the company and for dedicating a portion of your day to participate in our conference call this morning. With that, let's begin. I'm extremely pleased with the performance of the first quarter. Revenue and adjusted EBITDA were first quarter records, despite being negatively impacted by an estimated $13 million of revenue and $9 million adjusted EBITDA from severe weather conditions in January and February on the East Coast. As compared with last year's post-quarter, revenue increased 22.1% and adjusted EBITDA increased 36.3%, resulting in adjusted EBITDA margin improvement of 115 basis points. As you may recall, last year's first quarter was similarly impacted by weather and we had additional impact from the Southern California wildfires. Adjusted for the weather impact on this year's first quarter and the weather and wildfire impacts in last quarter's last year's first quarter, our margin improved by 52 basis points. There were a number of items in the quarter worth noting. First, we continue to see a shift towards advanced imaging. During this year's first quarter, 29.3% of our procedural volume was from advanced imaging, compared with 26.9% last year's first quarter, a difference of 235 basis points. This is both a function of overall industry trends as well as the significant capital investments RadNet has made in advanced imaging equipment, which is driving faster throughput and increased capacity. Additionally, the implementation of TechLive, Deep Health's remote scanning solution for technologists, has significantly benefited RadNet's MRI utilization by substantially decreasing exam room closure hours. TETCT procedure growth continues to be driven by studies to identify and stage prostate cancer and to detect brain plaques correlated with Alzheimer's and dementia. During the quarter, PET-CT procedures increased 35.2% in aggregate and 14.7% on same-centered basis. As a result of the operating strength of March, we exceeded internal projections for the first quarter embedded in 2026 full-year guidance. Additionally, the strong March performance has has continued throughout April and into the first part of May. The combination of these factors drove our confidence to raise 2026 full-year guidance for imaging center revenue, adjusted EBITDA, and free cash flow. This quarter was an active one for acquisitions. In the imaging center segment, two significant positions were completed at the beginning of January. First, Radiology Regional was purchased. the owner of 13 multimodality imaging centers in southwest Florida. For five decades, Radiology Regional, through its approximately 400 employees and over 40 radiologists, has been a fixture in the fast-growing communities of southwest Florida, spanning Naples to Sarasota. Second, we entered the Indiana market with the acquisition of Northwest Radiology, operator of six imaging centers in the greater Indianapolis area. Founded in 1967, Northwest Radiology has built a longstanding reputation for clinical excellence in central Indiana. We are busy integrating these two acquisitions, which includes deploying the many deep health AI-powered solutions intended to improve clinical accuracy and patient outcomes, streamlining operating processes, and bettering the patient experience. It is worth repeating that RadNet is not a buy-and-hold investor and operator. Instead, we target markets where there are further opportunities for growth and expansion through bringing the full capabilities of RadNet solutions to bear. This includes RadNet's evaluating acquisitions and DeNovo Center opportunities, launching AI-powered population screening programs, and deploying best practices for operating and clinical processes. And finally, on March 2nd, the Digital Health Division acquired Gleamer SAS in France, a fast-growing developer of a broad portfolio of FDA cleared and CE marked solutions for musculoskeletal, breast, lung, and neurologic applications. In particular, Gleamer is best known for its leadership in x-ray, where the breadth and scale of its cloud-first solutions are unparalleled. The integration of Glemer into deep health has begun, and we have already implemented Glemer's clinical x-ray AI in a number of Southern California locations. Case will discuss the Glemer acquisition in more detail during his prepared remarks. The hospital and health joint venture business continues to grow. On April 30th, we announced the commencement of a new partnership with Trinity Health St. Alphonsus Health System in Boise, Idaho. The venture currently yielding about $30 million in annual revenues will initially operate five centers that include two outpatient facilities at St. Alphonsus Medical Centers. Then it purchased a 51 percent interest in existing partnership entity for approximately $17 million, including this newly commenced Trinity Joint Venture, 155 of RADNAT's 440 centers, or approximately 35.2%, are held within health system partnerships. Other opportunities to establish new health system partnerships, including ventures that could expand RADNAT's geographical presence, are in the current pipeline. Health systems continue to seek long-term strategies for outpatient and inpatient imaging and may have recognized that cost-effective freestanding centers will continue to capture market share from payers and patients seeking lower cost and high quality. RADNA continues to be an operating partner of choice for those hospitals that recognize they cannot accomplish that outpatient imaging objectives optimally on their own. Finally, we continue to have strong liquidity and modest financial leverage. We ended the first quarter with a cash balance of $455 million and a net debt to the adjusted EBITDA ratio of slightly under two. So, a substantial amount of cash was spent in the first quarter on the acquisitions of regional radiology, Northwest radiology, and Gleamer causing radness leverage to increase. we continue to manage cash wisely and debt balances prudently we had a strong free cash flow will enable dereveraging in the coming quarters at this time I'd like to turn the call back over to mark to discuss some of the highlights of our first quarter 2026 performance thank you Howard I'm now going to briefly review our first quarter performance and attempt to highlight what I believe to

be some material items. I will also give some further explanation of certain items in our financial statements as well as provide some insights into some of the metrics that drove our first quarter performance. I will also provide an update to 2026 financial guidance levels, which were amended in conjunction with last evening's financial results press release. In my discussion, I will use the term adjusted EBITDA, which is a non-GAAP financial measure. The company defines adjusted EBITDA as earnings before interest, taxes, depreciation, and amortization, and excludes losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments, and non-cash equity compensation. Adjusted EBITDA includes equity and earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interest in subsidiaries and is adjusted for non-cash or extraordinary and one-time events taking place during the period. The full quantitative reconciliation of adjusted EBITDA to net income or loss attributable to Radnet Inc. common shareholders is included in our earnings release. I will also be using a second non-GAAP measure pertaining to the digital health segment called annual recurring revenue, or ARR. The company defines ARR as a key subscription economy metric representing the predictable, normalized, annualized value of contracted recurring revenue generated from customers from active customer contracts. ARR includes subscription fees, recurring support fees, and contracted usage charges, and excludes one-time, non-recurring fees such as implementation, hardware sales, professional fees, consulting, and one-off training. With that said, I'd now like to review our first quarter results. While I won't recap all the financial information that's contained in last night's earnings report, here are some of the highlights. We had a stronger-than-anticipated first-quarter results when we set our financial guidance levels initially. Despite being impacted by the severe winter weather conditions in January and February, lowering revenue by an estimated $13 million and adjusted EBITDA by an estimated $9 million, dollars, we were still able to achieve record first quarter revenue and adjusted EBITDA. Relative to last year's first quarter, total company revenue increased 22.1 percent and adjusted EBITDA increased 36.3 percent. The increase in revenue was primarily the result of the following. Our ability to grow same-center advanced imaging procedure volumes by 8.2%, the contribution from acquisitions which we completed over the last year, including in southwest Florida and Indiana during the first quarter, performance from de novo center openings over the last year, and the 51.5% increase in digital health revenue, partially driven by the acquisitions of ICADCMAR and Gleamer. During the quarter, imaging center segment adjusted EBITDA margin improved by 188 basis points relative to last year's first quarter. This comparison was aided by the fact that in last year's first quarter, we faced similar winter weather conditions, as well as the Southern California wildfires. But even when adjusting and normalizing our results for the winter weather conditions in both this year and last year's first quarter, as well as the California wildfires that impacted last year's first quarter, imaging center adjusted EBITDA margins still improved by 52 basis points. Our operations teams continue to implement digital health technologies that increase throughput and capacity, allowing us to serve more patients and a larger part of the growing demand for advanced outpatient diagnostic imaging. With respect to the digital health division, I'm going to let Case and Sham go over that in much more detail shortly. But in summary, the digital health segment is gaining momentum. Case and Shom, among other things, are going to outline the rapidly growing sales pipeline, discuss recent commercial successes, and provide a status update on the integration of recent digital health acquisitions and the implementation of the deep health solutions across the RadNet network of centers. We finished the quarter with a strong cash and liquidity position. At quarter end, we had $455.3 million of cash on the balance sheet and full availability of a $282 million revolving credit facility. Continued improvements in revenue cycle, particularly in the area of patient collections, have lowered DSOs, or day sales outstanding, to a RadNet record low of 29 and a half days, which we believe to be one of the best in the industry. This continues to provide the cash we require to fund our growth and expansion in both operating segments. With regards to our financial leverage, as of March 31, 2026, unadjusted for bond and term loan discounts, we had $631 million of net debt, which is our total debt at par value less our cash balance. Note that this debt balance includes RadNet's ownership percentage, which is 49 percent, of New Jersey Imaging Network's net debt of $23 million, for which RadNet is neither a borrower nor guarantor. At quarter end, our net debt to adjusted EBITDA leverage ratio was approximately two. Given the positive trends we experienced in March, April, and the first part of May, we elected to increase revenue, adjusted EBITDA, and free cash flow guidance ranges for our imaging center business. We increased revenue by $30 million at the low and high ends of the guidance range, increased adjusted EBITDA by $5 million at the low and high end of the range, and we increased free cash flow by $7 million at the low and high end of the guidance ranges. Otherwise, all guidance ranges for both the imaging center segment and the digital health segment remain unchanged. With respect to Medicare reimbursement for 2027, there's nothing to report at this time. As is typical each year, we are expecting CMS to release preliminary rates for the physician fee schedule sometime in June or July, at which time we will analyze CMS's proposal and our industry's associations and lobbying groups will provide CMS our industry's feedback. At the time of our second quarter financial results call in August, I will be in a position to comment on CMS's proposal and its impact, if any, upon RADNEXT's future results. I'd now like to turn the call back over to Dr. Berger.

Thank you, Mark. At this time, we're going to depart from our normal cadence in the script reporting here, which traditionally the third segment, I often comment on future trends in the industry. However, at this time, I think it's important for RadNet to establish its position in the market, which reflects the acquisitions and teams that we have put together over the last several years to substantially transform radiology workflow. This is a critical and important juncture in the history of radiology and, for that matter, healthcare. The challenges that the industry faces can only be met with the opportunities that technological advances provide us. And rather than this be a point solution, I'm going to turn the conversation over to Case and Sean, who will do a deeper dive into the digital health performance and provide a status update on many of our AI initiatives.

Case, please go ahead.

Thank you, Dr. Berger, and good morning, everyone. As we look back on the first quarter of 2026, it's clear that Deep Health's momentum is not just continuing, it's accelerating. Our strategic investments are positioning us to transforming radiology workflow. We are meeting this moment with a sense of urgency because the industry pressures we have discussed previously, radiologist burnouts, massive imaging backlogs, and staffing shortages, and these continue to build. Radiology cannot continue to operate on fragmented legacy systems. The volume of imaging studies is rising globally, while the supply of clinicians is stagnant. This gap can only be closed through the intelligent application of AI and cloud-native technologies. Deep Health's vision for transforming radiology workflow is that every imaging study should and will be read by AI, automating pre-interpretation workflows, and delivering an AI curated draft report to radiologists as they start their reading. And this isn't just about convenience. It's the optimal, scalable way to ensure high-quality, consistent care across the globe. To achieve this, we've moved beyond selling individual AI and informatics tools and point solutions to delivering an enterprise solution that brings together clinical AI, image management, and radiologist viewing and reporting. Today, the typical radiology workflow is a series of siloed manual steps, manual case assignments, jumping between different workstations, and voice dictating every finding from scratch. We are now replacing that with a novel, connected, comprehensive enterprise solution for medical imaging that enables four key deliverables. firstly cloud native AI analysis every study is automatically processed by a portfolio of native and third-party AI through our AI orchestrator AI studio which integrates both propriety and third-party clinical AI secondly dynamic case routing we're breaking down the walls between hospitals imaging centers urgent care facilities and any other imaging location and we're connecting the entire imaging ecosystem our platform routes cases to the most qualified available specialists regardless of where the images are acquired or where the radiologist sits thirdly AI curated drafts preliminary reports to through our reporting pro solution we provide radiologists with a pre-populated draft pre-populated drafts preliminary reports it shifts the Radiologist's role from generator to editor, allowing he or she to attend, correct, and accept signings far more efficiently. And fourthly, remote operations through our TechLive solution. We are virtualizing the technologist's role, allowing expert techs to support multiple scans remotely, ensuring quality and consistency. By unifying image management, clinical AI, and reporting into one seamless experience, we're delivering a new standard of care that addresses the core challenges of the imaging enterprise. And we are actively prototyping and validating this comprehensive workflow and clinical vision at RedNet, and our internal deployments are tracking in line with plan. We're seeing a significant productivity impact at RedNet as highlighted by some of the following examples. With TechLife, by implementing remote and assistant scanning, we've optimized technologist utilization, ensured that expert support is available for every complex scan, and maximized system capacity. This has been a key driver in maintaining high throughput despite the industry-wide technologist shortage, most notably by reducing exam room closure hours that Mark also mentioned. Clinical AI. Deep health and third-party AI solutions now cover over more than 70% of our studies across mammography, MR, CT, ultrasound, and x-ray, and we are capturing the benefits of that. For instance, we have now fully embedded thyroid ultrasound AI from our C-mode acquisition into retinette operations across nearly 300 sites. And the results are tangible. We have successfully reduced ultrasound stop times from 30 minutes down to 20 minutes across the board. This 33% increase in efficiency allows us to reserve more patients without increasing our physical footprint. And as of this call, we are alive with our X-ray AI representing more than 20% of volume in our California region. And then reporting pro, we are currently in the midst of a multi-region rollout with successful deployments in Florida and Texas. Radiologists using these AI-enabled reporting tools are reporting higher productivity and faster turnaround times. Now, let's have a look at the commercial results. The market response to our integrated offering has been very strong. We ended Q1 2026 with $97 million in annual recurring revenue, ARR, representing a 95% year-over-year growth. We are all planned to reach our target of more than $140 million in ARR by year-end. This confidence is backed by strong progress, a robust sales pipeline, and also the investments we have made in our commercial, deployment, and marketing capabilities. For instance, we currently have $7 million in signed ARR that's fully secured, but not yet reflected in our Q1 ARR, as these sites move through the go-live process in the coming months. On top of that, we've added significant Q1 wins in terms of securing $16 million in total contract value this quarter across 40 customers, reflecting a higher closure of deals and with an even split between and across different global regions. This includes, for instance, a $1.5 million total contract value diagnostic suite deal in North America and major long AI contracts across the UK and EMEA. The Q1 deal flow represents a healthy mix of small, medium, and large-sized deals which will provide more consistent and convertible ARR and revenue growth. And then we have a robust pipeline. Our commercial funnel is developing in line-grid plan with well over $150 million in commercial deal opportunities as measured in total contract value. Our acquisitions are performing ahead of expectations. Gleamer, which we closed in early March, exited Q1 in line with plan and is on track to exceed its end-of-year targets. And we've begun cross-selling its portfolio into the pre-existing deep health install base and vice versa. Furthermore, ICAD is seeing a significant acceleration in cloud-based demand, with a combination of 20 existing and new customers going live in Q1 alone, validating our strategy of moving customers from one-time licenses to a repeatable high-margin ARR model. PMODE has been deployed with deep impact at RedNet across 300 sites and we're now starting to see good commercial momentum evidenced by a recent thyroid ultrasound AI win, an external win, with a total contract value of close to $400,000. dollars. And CMAR, the image exchange platform powering the lung cancer screening program in the UK, amongst others, is performing a head of plan with a strong win in the national mammography screening space. Our innovation engine continues to deliver. We now stand at 26 FDA clearances and 22 CE marks. And before the end of this year, we would receive an additional 12 FDA clearances and 15 CE marks. The velocity of our regulatory approvals has grown by over 70% year-over-year. And accordingly, we will continue to fuel the most comprehensive AI and informatics portfolio in the industry for radiology. Next to expanding our scope of clinical AI solutions, we are also preparing for the launch of the next version of the Deep Health Diagnostic Suite, which incorporates critical enterprise capabilities for the hospital and the health system segment. further expanding our total addressable market. In summary, our Q1 performance reflects a business that is hitting its strides with strong momentum on ARR growth. As compared to last year's first quarter, we delivered 52% total revenue growth, and our external revenue, the revenue generated outside of RedNet, reached 64%, up from 51% from an installed base of close to 3,000 global customers. This shift proves that Deep Health is successfully transitioning into a global technology leader. Our adjusted EBITDA margin in the first quarter reflects the intentional margin impact from our recent acquisitions and continued infrastructure investments. We are exactly where we plan to be. These investments are the fuel which is enabling 2026 and future growth, and we are on plan to meet the guidance we have set out for 2026. Based on our current trajectory and the visibility provided by our science backlog and pipeline, we are reaffirming digital health full-year guidance. Total revenue at $135 to $145 million. Adjusted EBITDA at $10 to $12 million. We have the right strategy, the right technology, and the insights to deliver our solutions at scale. Thank you for your continuous support as we build the future of radiology. Operator, we are now ready for the questions and answer portion of the call.

Thank you. We will now begin the question and answer session. To ask a question, you may press star and 1 on your touch-tone phone. If you are using a speaker phone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then 2. At this time, we will pause momentarily to assemble our roster. The first question comes from Brian VanKilip from Jefferies. Please go ahead.

Hey, good morning. Congrats to the solid quarter.

Maybe, Mark, as I think first about, you know, the moving pieces in the clinic business, you know, obviously some strength and volume in the quarter. One, just curious, you know, if you think of this on a normalized basis, excluding weather from both sides, I mean, how should you be thinking about that volume growth and, you know, kind of like maybe also for Dr. Berger, the sustainability of the drivers there. And then the second part of the question for you, Mark, as we think about the acquisitions that you've announced in the JVs, just curious how we should be thinking about the ramp and the opportunity for upside from those acquisitions and partnerships.

Sure. Good morning, Brian. Yeah, so the performance, you know, is really being driven by a number of factors, some of which we mentioned in the script. But, you know, one of the, you know, really shining lights here is the performance of the advanced imaging and the growth that we're seeing there. We continue to see and experience a business shift in favor of advanced imaging. And, you know, we're regularly now seeing, you know, MRI volume, same center being in the high single digits this quarter. It was 10.1%. You know, CT we're regularly seeing kind of in the mid-single digits, and PET-CT, which continues to be driven by, you know, the brain amyloid studies and the prostate, you know, PSMA tests, we're seeing growth north of 14%. And as we've always said, the best, you know, and most profitable growth we can have comes from same center performance, where we can drive incremental revenue into the same fixed cost base. And when we do that, there's a lot of pull-through profitability. And, yes, there's a lot of moving parts on the cost side of our business, but this is, you know, the continued growth of advanced imaging has certainly driven, you know, the better than anticipated performance, you know, that, you know, we had in the first quarter and the beats that we've, you know, regularly had, you know, in past quarters. So we don't see anything to give us concern that this is going to change. I mean, you know, part of this is what's happening overall in the industry with respect to trends. You know, there have been a lot of advancements in the technology of the equipment that allows for better throughput, more capacity. A lot of what we're doing on the digital health side, which Case mentioned in his prepared remarks, you know, is all about driving capacity, creating a more efficient workflow that can drive more patients through the, you know, existing cost basis of the centers. And so I think, you know, we're feeling very positive about the trends in the business. As we mentioned, we had a very, very strong march. That performance continued into April and now through early May. And so we're feeling good about the business and how it's rebounded since, you know, the severe weather conditions that we faced in the Northeast in January and February. Howard, you want to add a second? I'm sorry.

Sorry, Brian, go ahead. You had a follow-up question?

Yeah, maybe my follow-up for Case, as I think about the wins that you've announced, I mean, Trinity here recently, and maybe some of the FDA approvals that are pending, how do we think about the ramp in revenue? I know you may say the guidance of the year, but as I think about the post-26, just thinking through the opportunities to drive revenue growth, again, both on these sides, on the clinical AI side and then also on the deep health kind of like OS side.

Thank you, Brian. Look, I think the most leading indicator, therefore, is how the commercial funnel is developing. I mentioned a funnel that's developed now towards and above the $150 million total contract value mark. This sits across our portfolio. So that's for, let's say, what we call diagnostic suite as well as enterprise operations. So diagnostic suite is more the tax business, enterprise operations is more the risk business, and clinical AI. We're seeing that momentum building in the funnel, which gives us confidence, A, that for this year we will achieve the 140 million ARR run rates, but also that will continue into 27 and beyond with the run rate, with the growth that we had set out for ourselves also during the investor day, which is above 30%. I would say I'm cautiously optimistic based on the confidence that we've also acquired, for instance, through Gleamer. that that commercial momentum of 30% is on the lower side. Now, then to revenue, because I think you specifically asked about revenue, obviously the difference between ARR and revenue is timing of deployment of these installs. And so one of the delivered investments that we've made over the last months is in deployment case, It's not just about winning these deals, building that commercial pipeline. And now I want to see a fast deployment of our revenue targets for the guidance of this year and ongoing growth.

Thank you, guys.

You're done with your question?

Yes, operator, we're ready for the second question. The next.

Thank you. Our next question comes from the line of Andrew Moore with Barcliff. Please go ahead.

Hi, good morning. I just wanted to follow up on that volume conversation. The same story, advanced volumes were strong in the quarter, up 8%, but I think that implies routine volumes were close to flat. Can you help us understand the underlying dynamics on the routine side? Is this simply different demand drivers, or is there also a crowding out effect from the strong advanced volumes that's weighing on those results?

Sure. I'll start with that, Andrew. Thanks for the question. Yeah, we're seeing, I mean, one quarter a trend doesn't make, and we've always cautioned investors about that. But we're definitely seeing disproportionate increases in advanced imaging in our centers. And we've focused, you know, in the last few years on upgrading equipment and capabilities to create more capacity in around advanced imaging. because as, you know, while routine imaging still represents, you know, close to 71% of all of our procedure volume, the other 29% of the, which is the advanced imaging, drives over 60% of our revenue. So clearly the focus is on driving advanced imaging. And we're seeing more and more clinical indications each year as the equipment gets better, as the technology gets better for advanced imaging. So there is certainly a shift in the overall industry and how health care is delivered in favor of advanced imaging, and that's where our focus has been. So, we have said in the past and continue to say that we still think the routine imaging is going to grow, but it will grow kind of in the way population grows, you know, and, you know, likely kind of in the low single digits, which is fine.

Yeah, Andrew, let me just add perhaps a little bit more color to that. The advances in technology cannot be overstated here, and the reason why there is such an increasing driver of advanced imaging is because there is a realization in all levels of healthcare that these tools are now capable of earlier and earlier diagnosis, which ultimately to better outcomes. There has not been any major changes in x-ray and some of the other routine imaging as there has been in MRI, CT, and PET-CT scanning. And I think it's a credit to the management on both the east and west coast to not only have realized that we needed to make the investment in the equipment and the technology, but also to expand the clinical capabilities that we have, which we put on full display at the investor day last November to help grow these practices and make certain that we achieve best practices with these tools. So I think we are following the trends and willing to deploy the resources, both human and financial capital, to take advantage of this, but to do it at an extraordinarily high level of quality for which I and the whole executive management team are enormously proud. But I think the seminal event today that we're trying to really outline is that all of this can be further enhanced by the new tools that we have invested in and which I think we have the broadest and most remarkable inventory of AI tools both on the clinical and on the generative side to help not only meet the demand of this growing need for imaging in general and advanced imaging in particular, but to give our radiologists the ability to focus not on the more routine, but on the part of the business which they have been trained for, and that is to identify abnormalities and act as a consultant rather than the drudgery that goes along with a lot of the routine workflows. So, I think you will see more and hear more about this in upcoming quarters as we not only fully roll out the AI capabilities internally, but we meet the opportunities that are presented to us with our current and future hospital partners.

And, Andrew, and I would add one other thing is that some of the digital health technologies that we're deploying now, I think will actually serve to drive some more growth in routine imaging. You know, for example, you know, we've talked in the past about the C-mode thyroid technology that now is, that Kate's mentioned is lowering scanning times, you know, by 50% for thyroid, which is roughly about 240,000 of our ultrasound exams. And when you look at the capacity that that is creating, you are seeing some growth in ultrasound on a same-center basis that grew about 2.1%. And as we get FDA approval, which we're expecting to this year on the breast ultrasound, which is another over 800,000 of our, you know, roughly 2.7, 2.8 million ultrasound exams, that's going to further, you know, speed up the center-level workflow to allow for more capacity, you know, for doing ultrasound. So, there are items, and, of course, the GLEAMR technology on X-ray will allow for our radiologists to, you know, to read those faster, you know, with more productivity, which will ultimately allow us to do more in the future. So, I think there are things that are coming and that we're implementing that will also drive some routine imaging growth.

Great. And then the new and acquired centers also appear to have a meaningful impact on volumes in the quarter. Can you talk about the integration of your clinic acquisitions and how that contributed to our performance? Thanks.

Yeah, so with respect to the acquisitions in Florida, southwest Florida, the 13 sites we bought from Lucid Health, as well as the sites we bought in Indiana. They contributed some to the first quarter, but, you know, not meaningfully. You know, when you look at the two of those on an annual basis are about $117, $118 million of revenue. So if you divide that by four, you're talking, you know, about, you know, $30 million or so of revenue in the first quarter. From an EBITDA perspective, it added, you know, about a couple million dollars, slightly less than that for the first quarter, you know, with all the seasonality. So we're just starting the implementation, or I should say the integration of those. They're going real well. They're both actually ahead of schedule. and we believe that both of those assets are on plan, if not ahead of plan, to reach their projected rate for 2026. So I think we feel real good about the integrations of those and the other deals that we did in the second half of last year in mostly in the New York metropolitan area.

And if I could sneak in one more on cash flow. You called out the record-load DSOs, and it looks like there's, you know, some unseasonally strong working capital in the quarter. Are these initiatives related or RCM capabilities linked to deep health or anything else you can provide color on driving the strength in working capital?

Yeah. No, it's really just continuing to improve in our blocking and tackling. We typically see a working capital build in the first quarter and an increase in our AR, you know, from the seasonality with respect to the deductible resets where, you know, we build a patient insurance companies in the first quarter and then have to collect a patient portion responsibility. But this year, I mean, we continue to see improvements. We're getting better and better at collecting the patient portion responsibility up front, where we've also aggressively gone back into some older aging buckets of our AR and are having some success collecting some of the older AR, both from commercial payers as well as patients. So I think, you know, the investments we've made in systems to, one, be able to identify up front what the allowable amount is based upon the patient's insurance, their plan, where they are in their deductibles, and then the ability to query the insurance company in real time to be able to identify whether the patient has a copayment or, you know, or where they are in their deductibles has allowed us to aggressively go after that money at the time of service. And we're even telling patients what their likely responsibility would be at the time of scheduling. And that's had a marked impact in our ability to, you know, to collect this money quickly. And I think our DSOs reflect that and probably are one of the best in the industry.

Great. Thank you.

Thank you. Next question comes from Sean Ramson with Raymond James. Please go ahead.

Hey, good morning. Mark, if we looked at the imaging segment, 26 over 25, what's a good number for the EBITDA contribution from M&A versus not M&A?

Yeah. Most of it is from, saying, center performance, as I mentioned on the earlier question. About a couple million dollars of EBITDA came from the recent acquisitions in the first quarter.

I'm talking about the year, full year over full year. If we take 2625 full year, what does that look like?

Yeah, the majority of our EBITDA growth, the vast majority, about two-thirds of it, is coming from same-center performance as well as de novo performance, which I also, you know, include as organic growth, and about a third, slightly less than a third, is coming from the contribution of acquisitions.

Okay, and then, you know, following your digital health journey is dizzying at times. If we were to look at 2026, of all the things that you've rolled out, digital, I mean, the TechLive, the SmartMemo, what one or two modalities is driving the most EBITDA today? And then if we looked at a couple of years, what are some emerging capabilities you have that aren't quite monetizing to shit? And that could be either in your imaging segment or in your digital health segment. What's the – how do we think about the – and can we also, just to sneak one else in there, can we confirm that this year is the trough margin for digital health? And then how do we think about margin versus investment over the intermediate term?

Mark, you want me to take it? Yes, please Yes, great question So, as per the Investor Day We have a horizon towards 2028 Rolling out the various solutions That we have currently line of sight Of in the digital health segment And deploying those at RedNet And I think both for Actually across clinical AI which is really a modality-by-modality focus where we started in mammography, we've expanded to thyroid ultrasounds, we're going to deliver breast ultrasounds. We are now deploying X-ray. I think you will continuously see an increasing penetration of AI and the impact thereof. We are currently covering 70% of the clinical AI solutions with deep health solutions and third-party solutions, roughly 60% for default solutions and the remainder third-party AI. But that doesn't mean it's fully penetrated because we haven't captured the full productivity nor the full TCOG reimbursement from these solutions. So think of it as if you want to use a number, you know, a third implemented on the clinical AI roadmap and more to come. Then the second key area is what we call the diagnostic suite, where we've deployed certain capabilities, such as the viewer, but we're now also rolling out, as mentioned in my prepared presentation, the reporting pro solution, which gives further benefits to reporting productivity and so on and so forth. So, also there, there's more to come, and I think we're a little bit less advanced in implementation today and will peak towards the end of the year into next year. And then on the operations suite, which is really risk enhancements, we've made initial steps, for instance, in the context center that we previously talked about, but there are all kinds of agentic AI solutions that we have in the pipeline, which will further substantiate productivity impact in line with what we presented at Investor Day. So think of it as a three-year roadmap. What's new today, which we presented, is really the header that's where we said transforming radiology workflow, which means that four elements of the solutions, four types of solutions that I just talked about, actually are combined into one, which is clinical AI together with AI orchestration, together with the diagnostic suite, together with the reporting solution, allow you to transform the radiology workflow and generate automated drafts preliminary reports. That's a new idea, and that is now with the acquisition of Gleamr, we're deploying that in an accelerated way for X-Ray. That shows that our innovation funnel will continue to build and will continue to invest in that. And so the way I would answer the question is we're well on track for the margin impact that we set out during Investor Day. But we're also seeing new innovation opportunities to come. And so we're making progress. We definitely will not have reached the end of the productivity drive this year nor next year as we continue to fuel the funnel.

And just lastly, there was an interesting article recently about this reporter went through, you know, the whole breast cancer AI. and the point was made in the article that AI for MAMO is really good at, you know, the negative reads are really tight, but it tends to overread the positives, you know, and that's where you need the human intervention to override sometimes the AI gets it wrong. What are you seeing in terms of your false positives, and is that trending in a particular action, or is false positives just kind of the way this works, that it throws things out there and then the radiologist has to play catcher to make sure that the machine didn't hallucinate, if you will.

I would say both are of absence focus in terms of improving and learning the model. But maybe, Sam, you can elaborate a little bit more on how that's approached in practical life.

Yeah, absolutely, Keith. I think, first of all, the breast cancer detection, anything that we're doing with function detection, isn't a generative model, it's really a task-specific model. So, you know, there's no concept of hallucination, if you will, there, but it's much more trained on the data and adapted when we see those false positives, let's say, in the RADNED population. So, what we've done very well, also because of the closing that we have with RADNED, is we're able to adjust that. you know, through, you know, results from radiologists through incorporating things like proper studies where we're reducing the false positive rates on a fairly regular basis. Remember, we have essentially 1.6 million to 2 million mammals that we're processing every year and the, let's say, false positive from those we're also processing every year And we're learning and we're improving to a point where the AI system is just as good as the radiologist, if not better than the radiologist. And I think, you know, we build these as candidates for potentially driving also autonomous type of detection as we go forward.

Thank you very much. Thank you. Next question comes from Grayson McAllister with Trish. Please go ahead.

Hey, guys. This is Grayson McAllister on for days. Wanting to follow up on the JV with St. Alphonsus, you talk about it as being a blueprint for future health system partnerships. I guess could you just talk a little bit about what aspects that this JV includes that maybe previous didn't, and then specifically around deep health, how does this improve the offering to systems out there, and what are you seeing in the pipeline specifically around JVs?

Maybe Howard, do you want to add one more?

Yes. I think the importance of the announcement was our first opportunity to implement all of the tools that we bring right now to the table to make a more seamless experience, not only for the radiologists, but also for all of the stakeholders that either perform imaging or need to see imaging results. As a result of this, within about 120 days, when we fully implement the deep health operating system, The radiologists will get the benefit of doing both their reading and reviewing studies, outpatient and inpatient, on a single platform. We'll be able to use the variety of AI tools to help manage better their reading and interpretation, and we'll begin using the reporting pro tool that Case described that will allow more automation in the reading material. But the bigger picture is what we want to do with this health system and others, and that is to connect all the other providers that are using or providing imaging services in the health systems platform. That could be urgent care centers, physician offices, emergency rooms, anybody that produces imaging will be part of our cloud-native solution that will allow not only for the implementation of reading from any site by the most qualified and most available radiologists, but getting those results faster and on a timely basis to both the physicians and the patients that require that information. So, the transition that we're talking about, which is a blueprint for the models with other health systems that we currently have relationships with in joint ventures, as well as others that we're in deep conversations with, is really a transformative process of the entire radiology and imaging workflow solution, which we hope to be able to better demonstrate in the third quarter of this year.

Got it. Okay, and then just following up on Gloomer, I believe around the announcement you guys talked about some training of the sales force that had to happen before you can really start to see the crawl cell opportunity take off. So just wanted to check on what ending you think you're in now as far as capturing that cross-sell opportunity, and where would you expect to be by the end of the year next?

We're deep into training, but not waiting for training, which basically means that we have the first cross-sell opportunities happening today in the U.S., but also outside of the U.S., and on an ongoing basis, we're going to go deeper into roadmap training, competitive pitching, integrated portfolio offering, and so on and so forth. But it's highly iterative because we don't want to wait for something. And quite frankly, the professionalism of the Gleamer team, commercial team, but also obviously of our legacy team, they seek these opportunities. And so they're burning to bring these new cross-sell opportunities in. It has momentum already.

Thank you.

Operator, if you allow me, I just realized that in the previous question, there were two questions about the impact on margins. And the second question was related to if for a digital health segment, this was a trough year in terms of margin development. I just want to confirm in line with what we said with the investor day, that's indeed the case. And so driven by the previous acquisitions and also the investments that we've made out as per our plan, we see lower margins in the Q1 results and will climb up gradually towards the end of the year to increase margins again, assuming no major dilute of acquisitions, which are currently not planned.

Thank you. Our next question comes from Matthew Girmour from KeyBank. Please go ahead. Good morning, and thanks for the question.

I wanted to ask about EBITDA seasonality. Mark, in prior calls, you've commented about 1Q being impacted by seasonal expenses, including payroll taxes and expensing of bonuses. Can you maybe quantify some of those P&L costs that impact the first quarter but then fade in subsequent quarters? And if you had any broader comments about the cadence of EBITDA, that would be great.

Yeah, so EBITDA is seasonably low in the first quarter. It's partially due to trends within the healthcare delivery system in general, meaning that, you know, patients' deductibles reset, you know, starting January, and there just tends to be lower utilization in the early part of the year within health care and as patients are shouldering more of the burden of those expenses themselves. And then as the year goes by, we see growing utilization throughout the year. Also, with winter weather conditions and holidays in the first quarter, we often see some lower volume. And then, as you correctly suggested, the payroll taxes for certain of the payroll taxes max out for the highly compensated individuals, you know, including our radiologists, our professional fees in the first quarter and are lower throughout, you know, through the rest of the year. And then the way we pay an expense, certain employee bonuses, that hits all in the first quarter. So, we will see a significant jump up in our EBITDA in the second quarter and beyond as planned and as is typically seen in our business in past years, and that's built into our guidance. The exact numbers of what those, you know, those payroll expenses are and those bonuses, I don't have at my fingertips right now. But you'll see if you go back to 25 and 24 and 23, you'll see a similar impact in the first quarter each year.

That's great. And then as a follow-up, I wanted to ask about the reimbursement side of AI. You know, you all have mentioned 70% of studies could be leveraging AI by the end of 2026. Can you give us a sense for where you're able to bill for AI solutions and just how to think about the incremental revenue opportunity over the next few years? Sam, do you want to talk about that? Let me do that.

Go ahead. Oh, go ahead, Sam.

We were talking about where you see the opportunities for reimbursement for AI.

Yeah, exactly. So, as you saw, we've seen in ultrasound, in the ultrasound case, there is essentially in ultrasound in MR and in CT, there are really generic key codes in each one of those areas, right, that support quantification and measurement related to various diseases in those modalities. So, in the ultrasound case, we see reimbursement now already from thyroid as we get approval for breast ultrasound, which is actually three times the volume of thyroid ultrasound. We can leverage the same reimbursement code for the breast there. In CT, there are applications such as lung detection with the characterization as well as quantification because we've measured the lung nodules, again, those can be reimbursed for the CT characterization code. And in MR, there are similar codes, and we plan to do that for our neuro product which we received FDA approval earlier this year, which has both quantification and characterization elements. And just remember, in neuro MR, there's more than a million studies. So, there's significant upside on the key code reimbursement side, which is not what Chase was talking about earlier, but we've not fully taxed because number one, you have to deploy the solution, implement it, then we have to start billing that, and then individually, we have conversations with the different payers to cover it, and then eventually, you get at increasing and increasing percentage coverage. An example of the thyroid where essentially when we started earlier on the quarter of the insurers were covering the T code, now we're, you know, in the 60s to 70s percentage of insurers covering it at the full rate. So that's part of the cascade as we deploy these solutions and then plan out the reimbursement scenarios. And naturally, as we show that, there's tailwind also when we go commercially now, because we've shown that these products can be reimbursed, that provides a natural tailwind, a natural tailwind as we then take these solutions to the flow.

Great, thank you.

Thank you. Next question comes from Larry Sholo from CJS Securities, please go ahead.

Great, thanks. Good morning, guys. And thanks for all the good information that came from the prepared remarks. A follow-up on the trajectory of the profitability in direct health. I think that's been a concern in the market and probably exacerbated by the pressure on the AI stocks and whatnot. I know you shared with us that the analyst day margin target, so I think 20%, even down margin. I believe we took a little bit of a step back intentionally with the Gleamer acquisition and probably some enhanced investment. But can you just kind of give us, you know, an update on that? You know, where do you expect, you know, when do you expect now to kind of get back into up towards that 20%? And, you know, longer term, is this still a 30%, 40% kind of market business?

Yeah, great question. Let me dive a little bit more deeply into even what we're seeing today. So, when we dissect our business into the core that's organically growing, the acquisitions that we did last year, and then the investments that we do, we see actually quite a healthy picture. So, the core that's organically growing today is already operating at, let's say, 30 to 40, more 40% EBITDA margins. The acquisitions in this public information that you've also seen in previous announcements, they are typically loss-making. And so, that has a short-term dilutive effect of what you should see is that we, for instance, been able to slightly ahead of plan, been able to get ICAT already profitable, so break-even as we speak today. and we're on the same trajectory also as we as we set out the opportunity that we might take a little bit longer but not because of quality of business purely because of the investments that we're doing in the x-ray space then thirdly in line with what we said invest investor day is and we're strengthening the business we're seeing on strengthening the business we're investing in the core business on the condition that we have line of sight of growth. Now, I walked you through the ARR growth that we foresee for the year, the momentum that we're building on the commercial funnel. And accordingly, we've prudently invested into a variety of capabilities, and I think of service delivery, implementation capability, also the commercial team. And that short term has an impact on lowering the EBITDA margins, again, in line with what we first saw for Q1, but also how we want to close the year as per our guidance. And so, in a way, nothing has changed versus what we set out on Investor Day. We're actually seeing a core business, an organic business, performing at an EBITDA margin at 30% to 40%, but we are strategically investing both organically and inorganically, and that on the short term has a dilutive impact. Now, you might ask, therefore, is the 20% towards 2028, is there upside to that? Possibly so. But I also want to recognize that we continue to find new opportunities to invest in, also in terms of our R&D platform. And we're really building a long-term sustainable business. And that was most always the reason why we saw the opportunity to invest. and therefore over the horizon of 26, 27, somewhat lower margins than you would typically expect of peers.

I appreciate all that. And I guess a little bit harder to measure, but just on the internal benefits, it sounds like a lot of, you know, lots of things are happening on the good side, but it feels like we're probably still way in the early innings on the internal benefits for you guys. Is that fair to say?

A little bit further. I mean, I watched a baseball game last week. I think – is that the first or the second thing? Somewhere – sorry, I'm Dutch. So that's the game. Yeah, no, that's fair. I would say – look, I used the term earlier in this call that we're at sort of one-third based on what we know today. So let me explain what I mean by that. We've deployed quite a bit. We see tangible impacts from the solutions that we've deployed. I talked about tech life. I talked about thyroid ultrasound. And those have meaningful growth impact into the bottom line of Rednext, offsetting, you know, some of the other headwinds that exist in the business, such as, for instance, inflation on salaries. But, and so there's a lot more to come in the coming 18 months. But we've also seen that we continue to generate new ideas, new innovations that will have further impact. And so, you know, are we one-third there, a quarter there? I don't think we're halfway there, but we've got significant opportunities still to capture. Great. Thank you.

I appreciate all that.

Thank you. An execution comes from Yuanzi with P. Riley. Please go ahead.

Thank you for taking our questions. I may be asking about the 70% question differently. You mentioned 70% of RedNet readings or studies could be running through clinical AI by year-end, 2026. So where are we now, and how do you see that impacting your labor costs and any other impact on your operation?

So maybe to clarify, and Sham, please confirm also, but today we're at 70% of the RedNet volumes use a form of AI. roughly 60% is deep health AI, and then 10% is third-party AI that's deployed at RedNet. As Sam also mentioned, we're seeing two key value levers here. One is productivity, so more effective reading or more effective interpretation. The other is the onset of possible T-codes that you can get built for. So, the productivity we're capturing today, the key codes initially are set out for more in the ultrasound domain for thyroid, but Sham also mentioned ultrasound breast in the future, and then CT and MR to come. So, whilst the penetration is high, the productivity gains are being captured, and the billing gains are in early stages of being captured. Sham, anything to add?

Yeah, maybe just to clarify a bit of comments, so when we say that the target is to be applying all of our AI to about 70% of the volume by the end of the year, the reason we believe we can achieve that is almost all the AI tools that we would deploy to achieve that target, we are now currently either in early stages of deployment or in mid-stages of deployment. So, for example, we just started the X-ray deployment. That's about 20% of our volume. If you kind of look at that as a large chunk, if we talk about NibirMR, I talked about a million studies out of our, you know, nearly 12 million studies that we do. So, we started these projects, but they're not fully deployed, and we anticipate they'll be fully deployed by the end of the year. And really, the primary savings are both the productivity of radiologists, as Case just mentioned, where we can actually free up their capacity to do more studies. And then the second piece is, of course, several of these have their own reimbursement elements as well.

Got it. Maybe a question to Mark. Can you help us reconcile the updated revenue guidance? Was it mainly due to the acquisitions or was there some contribution from the existing fleet?

Sure, yeah. So, when we put together the guidance, which we released originally in early March, we had already announced and incorporated the acquisitions of Northwest Radiology in Indiana as well as the Florida, the Southwest Florida operations. So, when we increased the guidance levels, the low end and the high end, by $30 million last night, that doesn't have to do with acquisitions. That's all about the fact that we're seeing strength in our business to the point where we think that we're going to overachieve our original budget and projections that, you know, we have internally that we set the guidance around. So, we're seeing, you know, strong same center performance, the digital health initiatives are bringing, you know, more capacity to our centers, and we're, you know, feel very confident that, you know, we were going to overachieve our original guidance levels.

And one last question from me, in terms of capitated contracts, do you see a possibility to combine your imaging offering with others, such as oncology treatment or Alzheimer's disease treatment, to win new capitated contacts from payers?

Well, we do work with other companies that do take risk for patient care in oncology and in other specialties. Today, we don't subcapitate with any of those groups who are taking risk on the specialty side. Predominantly, all of our capitation, you know, contracts are with large primary care or multi-specialty groups that are taking risk for the entire, you know, entire patient care. And then we subcapitate for all of the imaging. But there is an opportunity. There are some companies, I know you're aware of some, and I know you cover one or two companies that are in particular specialties that just take capitation risk for that specialty. And, you know, is there an opportunity? We do work with some of those companies right now on a fee-for-service basis. Would there be an opportunity to capitate with them on imaging? I think it's possible, depending upon price. I mean, ultimately, the financials have to work for us, and we have to make sure that the capitated rates that we get are in line with fee-for-service, you know, market-based fee-for-service rates, which is why we've actually pared down our application business slightly over the last couple years where we had situations where our reimbursement on some of those contracts were falling behind what we would otherwise be able to get on a fee-for-service basis, and we flipped them to fee-for-service relationships, and that's increasing our profitability. So I think the opportunity, Yuan, is there, but, you know, it ultimately depends upon, you know, what kind of rates we could get.

Thank you for the call.

Thank you. Our next question comes from Jim Sidoti, from Sidoti & Co. Please go ahead.

Hi, good morning, and thanks for taking all the questions. I know it's a long call. So if you include the new centers in Idaho, plus anything you've opened up so far this year, what is the total number of imaging centers you have?

So if you include the five that we bought in Idaho, we have 440 locations.

And you said earlier in the call that advanced imaging was now about 29% of revenue, I think about, so 29% of procedures, 60% of revenue.

Is there a target for advanced imaging over the next, let's say, five years?

Do you think that could approach 40% of procedures?

I don't think we really know. I mean, that 40% seems a little high because we've always prided ourselves on being a multimodality provider and will always be a multimodality provider. I mean, we think it's important from a marketing perspective to be able to market to our referring physician, you know, communities as a one-stop shop for all of their imaging needs. And often we will have patients sent to us for routine studies like x-rays and ultrasounds, and based upon the results of those studies, they'll be sent back to us for the more advanced imaging. And then, you know, back to tying into capitation in California, where we're taking risk on, you know, about a million and a half lives, we need to be a multimodality provider because, you know, 70-plus percent of what those patient populations need with respect to their imaging procedures are routine studies. So I think we'll always be somewhat, Radnitz modality mix will always be somewhat reflective of the overall outpatient imaging marketplace with respect to our modality mix. But what we have been very effective in, you know, in more recent times, particularly with the digital health tools, is to help drive up the capacity of advanced imaging by lowering scan times at our centers and making a radiologist more productive on the back end so that they can read more of these studies. And I think that that trend is going to continue within our business. So I think we're confident and optimistic about advanced imaging continuing to play a bigger role in the health care delivery system and in our business. We just don't know where that pops out.

All right. So you think more reasonable is maybe in the low 30s. Do you think that could level off?

We don't really know, Jim, but, you know, we're approaching 30% now, And so I think it's likely that we will go north of 30%, but I don't know if it where we'll max out.

Got it.

Thank you. As there's no further question, this concludes our question and answer session. I would like to turn the consent back over to Dr. Howard Bogle, President and Chief Executive Officer, for any closing remarks.

I would do so. thank you operator again i would like to take this opportunity thank all of our shareholders and stakeholders for their continued support and the employees of radnet for their dedication and hard work management will continue its endeavor to be a market leader that provides great services with an appropriate return on investment for all the stakeholders thank you for your time today I look forward to our next call today thank you the conference has now concluded thank you for attending today's presentation you may now